7 September 2020

Back British biotech by improving the clinical trials process

Andrew Boyle, CEO of LGB & Co. Limited, wrote an article for Pharmiweb on how to improve the British biotech sector.

The UK has a thriving life sciences sector. With three of the world’s top ten universities in the field – Oxford, Cambridge and UCL – plus prominent bioscience clusters in other British university cities such as Nottingham and Cardiff, UK research accounts for 12% of all life sciences academic citations worldwide (and nearly a fifth of the top 1% of these).

To read the full article, please click here.

Recent Articles

10 November 2020

MPE Properties Ltd. redeems loan notes in full

In March 2015, MPE Properties Ltd raised £1,050,000 through the issue of medium term notes under the terms of a loan note programme arranged by LGB.

Read more

9 November 2020

FTSE100 rockets as investors see light at the end of the lockdown tunnel

Andrew Boyle, CEO of LGB & Co., commented in a ProActive Investors piece on the Pfizer vaccine announcement. 
 

Read more

News & Insights

3 November 2020

Pre-election IPO rush set to slow in Europe, Asia

Ivan Sedgwick, Investment Director at LGB & Co., contributed to an article on Bloomberg on the impact on IPOs in the run up to the US presidential election.

Read more

News & Insights